MISTY RALYEA: Open Payments
NPI 1386949873 · LINCOLN, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$901 in 46 payments from 14 companies in 2025. Trend: 2023 $382 · 2024 $590 · 2025 $901
Food & beverage: $901
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 11 | $226 |
| ABBVIE INC. | 10 | $177 |
| Novo Nordisk Inc | 8 | $150 |
| Otsuka America Pharmaceutical, Inc. | 2 | $59 |
| GlaxoSmithKline, LLC. | 2 | $53 |
| Axsome Therapeutics, Inc. | 2 | $38 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $33 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $33 |
| Amgen Inc. | 2 | $31 |
| Dexcom, Inc. | 1 | $25 |
Products named: AIRSUPRA, VRAYLAR, Ozempic, REXULTI, TRELEGY ELLIPTA, Auvelity, BREZTRI, JARDIANCE.
Industry payments across AL — which companies pay providers there.
